In8Bio Inc (INAB)

$1.60 -0.03 (-1.54%)
Market Cap 16.00M
Revenue (ttm) 0.00
Net Income (ttm) -19.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,400
Avg Vol 67,244
Day's Range N/A - N/A
Shares Out 9.85M
Stochastic %K 64%
Beta 0.08
Analysts Strong Sell
Price Target $5.00

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an alloge...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
topstockalerts
topstockalerts May. 12 at 9:23 PM
$INAB this has been a very orderly climb
0 Β· Reply
IN8bio
IN8bio May. 12 at 4:50 PM
We’ll be hosting our R&D Day on May 21, 2026, with updates on our: β€’ Glioblastoma (GBM) program β€’ Gamma-delta T cell engager platform Virtual and in-person options available πŸ‘‡ πŸ”— Register here: https://investors.in8bio.com/investor-day $INAB
0 Β· Reply
JSP_Dilution_Player
JSP_Dilution_Player May. 11 at 3:24 PM
$IMMP $APRE $INAB at ASCO as well. NO POSITION... just watching for now
0 Β· Reply
Berakhot
Berakhot May. 11 at 3:51 AM
$INAB https://markets.businessinsider.com/news/stocks/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-r-d-day-and-medical-conferences-1036112992
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 8 at 1:20 PM
πŸŒ… Watchlist part 2 βœ… $AEHL .80 support, if above 1, have potential to 1.30/.50 βœ… $CTM .70 support, if above .85, have potential to 1/1.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 8 at 3:29 AM
πŸŒ… Watchlist part 2 βœ… $AIIO .75 support, if above 1, have potential to 1.30/.50 βœ… $ANNA low 3.15 support, if above 3.65, have potential to 3.80/4.20 βœ… $RXT 3.20 support, if above 3.60, have potential to 3.80/4 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 6:40 PM
⏳️ Potential swing ideas πŸ’‘πŸ’‘ βœ…οΈ $MRKR recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell therapies for hematological malignancies and solid tumors, HC Wainwright price target $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8.X, Brookline buy rating βœ…οΈ $INAB previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone, achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (Ξ³Ξ΄) T cell-based therapies targeting cancer and autoimmune diseases
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 1:26 PM
πŸŒ… Watchlist βœ… $GLE .60 support, if above .75, have potential to .85/1.20 βœ… $ATRA low 7 support, if above 7.60, have potential to 8/8.50 βœ… $ERNA 6.50 support, if above 7, have potential to 7.50/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 1:26 PM
πŸŒ… Watchlist part 2 βœ… $RMSG 1.50 support, if above 1.80, have potential to 2/2.40 βœ… $SABR low 2 support, if above 2.35, have potential to 2.50/.70 βœ… $NNBR 2.60 support, if above 3, have potential to 3.40/.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 2:17 AM
πŸŒ… Watchlist PART 2 βœ… $BYND slow and steady, trying to hold $1 ⚠️ $CHSN 1/100 reverse split, new price ~1.56 ⚠️ $CVNA 5/1 forward stock split, new price ~77.8 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
Latest News on INAB
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026, 4:30 PM EDT - 5 days ago

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

May 6, 2026, 8:00 AM EDT - 7 days ago

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 10:30 AM EDT - 26 days ago

IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 3, 2026, 4:00 PM EDT - 5 weeks ago

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Mar 12, 2026, 4:01 PM EDT - 2 months ago

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 2 months ago

IN8bio Transcript: TD Cowen 46th Annual Health Care Conference

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio appoints Kate Rochlin as president

2026-02-09T13:26:52.000Z - 3 months ago

IN8bio appoints Kate Rochlin as president

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Feb 9, 2026, 8:00 AM EST - 3 months ago

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Feb 5, 2026, 3:00 PM EST - 3 months ago

IN8bio Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Feb 3, 2026, 8:00 AM EST - 3 months ago

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio files to sell 14.38M shares of common stock for holders

2026-01-20T22:00:29.000Z - 4 months ago

IN8bio files to sell 14.38M shares of common stock for holders

IN8bio presents Phase I/II data from INB-200 trials

2026-01-12T13:35:56.000Z - 4 months ago

IN8bio presents Phase I/II data from INB-200 trials

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Jan 12, 2026, 8:00 AM EST - 4 months ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

IN8bio prices 5.13M shares at $1.38 in private placement

2025-12-19T13:05:25.000Z - 5 months ago

IN8bio prices 5.13M shares at $1.38 in private placement

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Dec 19, 2025, 8:00 AM EST - 5 months ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

IN8bio files $200M mixed securities shelf

2025-11-07T22:15:23.000Z - 6 months ago

IN8bio files $200M mixed securities shelf

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 4:00 PM EST - 6 months ago

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio expands INB-100 Phase 1 trial with new clinical site

2025-10-29T12:06:14.000Z - 7 months ago

IN8bio expands INB-100 Phase 1 trial with new clinical site

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 29, 2025, 8:00 AM EDT - 7 months ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

IN8bio presents new preclinical data from INB-619

2025-10-27T12:26:30.000Z - 7 months ago

IN8bio presents new preclinical data from INB-619

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Oct 27, 2025, 8:00 AM EDT - 7 months ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

IN8bio price target adjusted to $4 from $60 at Mizuho

2025-10-13T11:51:17.000Z - 7 months ago

IN8bio price target adjusted to $4 from $60 at Mizuho

IN8bio reports Q2 EPS ($1.24), consensus ($1.80)

2025-08-07T20:08:08.000Z - 9 months ago

IN8bio reports Q2 EPS ($1.24), consensus ($1.80)

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 4:00 PM EDT - 9 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

IN8bio recognizes 4-years in remission for patient treated with INB-200

2025-06-09T11:21:17.000Z - 1 year ago

IN8bio recognizes 4-years in remission for patient treated with INB-200

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 9, 2025, 7:00 AM EDT - 1 year ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Inc trading halted, news pending

2025-06-05T23:50:13.000Z - 1 year ago

IN8bio Inc trading halted, news pending

IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM

2025-06-02T11:50:11.000Z - 1 year ago

IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

Jun 2, 2025, 7:30 AM EDT - 1 year ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

IN8bio announces preclinical data from its INB-619 program

2025-05-14T12:27:42.000Z - 1 year ago

IN8bio announces preclinical data from its INB-619 program

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

IN8bio presents data on DeltEx Allo manufacturing program

2025-05-12T12:23:55.000Z - 1 year ago

IN8bio presents data on DeltEx Allo manufacturing program

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary Ξ³Ξ΄ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 12, 2025, 8:00 AM EDT - 1 year ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary Ξ³Ξ΄ T cell Manufacturing Generates Consistent and Robust Clinical Products

IN8bio reports Q1 EPS (7c), consensus (7c)

2025-05-07T20:07:40.000Z - 1 year ago

IN8bio reports Q1 EPS (7c), consensus (7c)

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio announces new preclinical data from gamma-delta T cell engager platform

2025-04-28T12:20:58.000Z - 1 year ago

IN8bio announces new preclinical data from gamma-delta T cell engager platform

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (Ξ³Ξ΄) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (Ξ³Ξ΄) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360Β° Conference 2025

Mar 18, 2025, 8:05 AM EDT - 1 year ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360Β° Conference 2025

IN8bio price target lowered to $6 from $8 at H.C. Wainwright

2025-03-14T12:35:10.000Z - 1 year ago

IN8bio price target lowered to $6 from $8 at H.C. Wainwright

IN8bio reports Q4 EPS (8c), consensus (8c)

2025-03-13T20:25:08.000Z - 1 year ago

IN8bio reports Q4 EPS (8c), consensus (8c)

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 13, 2025, 4:05 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 10:30 AM EST - 1 year ago

IN8bio Transcript: TD Cowen 45th Annual Healthcare Conference

IN8bio announces gamma-delta T cell enager platform

2025-03-03T14:36:54.000Z - 1 year ago

IN8bio announces gamma-delta T cell enager platform

IN8bio Announces Advanced Gamma-Delta (Ξ³Ξ΄) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Mar 3, 2025, 9:28 AM EST - 1 year ago

IN8bio Announces Advanced Gamma-Delta (Ξ³Ξ΄) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 11:00 AM EST - 1 year ago

IN8bio Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 14, 2025, 9:00 AM EST - 1 year ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Transcript: Study Result

Feb 11, 2025, 8:30 AM EST - 1 year ago

IN8bio Transcript: Study Result

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Feb 11, 2025, 8:00 AM EST - 1 year ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Transcript: Biotech Showcase 2025

Jan 14, 2025, 5:00 PM EST - 1 year ago

IN8bio Transcript: Biotech Showcase 2025

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 2:30 PM EDT - 1 year ago

IN8bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio Transcript: H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 25, 2024, 2:30 PM EDT - 2 years ago

IN8bio Transcript: H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 13, 2024, 4:01 PM EDT - 2 years ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

Jun 3, 2024, 6:05 AM EDT - 2 years ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 2 years ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 14, 2024, 10:00 AM EDT - 2 years ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 30, 2024, 6:05 AM EDT - 2 years ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 16, 2024, 4:05 PM EDT - 2 years ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Apr 9, 2024, 4:30 PM EDT - 2 years ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 14, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 2 years ago

IN8bio to Present at Upcoming Investor Conferences

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Feb 14, 2024, 8:00 AM EST - 2 years ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

topstockalerts
topstockalerts May. 12 at 9:23 PM
$INAB this has been a very orderly climb
0 Β· Reply
IN8bio
IN8bio May. 12 at 4:50 PM
We’ll be hosting our R&D Day on May 21, 2026, with updates on our: β€’ Glioblastoma (GBM) program β€’ Gamma-delta T cell engager platform Virtual and in-person options available πŸ‘‡ πŸ”— Register here: https://investors.in8bio.com/investor-day $INAB
0 Β· Reply
JSP_Dilution_Player
JSP_Dilution_Player May. 11 at 3:24 PM
$IMMP $APRE $INAB at ASCO as well. NO POSITION... just watching for now
0 Β· Reply
Berakhot
Berakhot May. 11 at 3:51 AM
$INAB https://markets.businessinsider.com/news/stocks/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-r-d-day-and-medical-conferences-1036112992
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 8 at 1:20 PM
πŸŒ… Watchlist part 2 βœ… $AEHL .80 support, if above 1, have potential to 1.30/.50 βœ… $CTM .70 support, if above .85, have potential to 1/1.20 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 8 at 3:29 AM
πŸŒ… Watchlist part 2 βœ… $AIIO .75 support, if above 1, have potential to 1.30/.50 βœ… $ANNA low 3.15 support, if above 3.65, have potential to 3.80/4.20 βœ… $RXT 3.20 support, if above 3.60, have potential to 3.80/4 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 6:40 PM
⏳️ Potential swing ideas πŸ’‘πŸ’‘ βœ…οΈ $MRKR recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell therapies for hematological malignancies and solid tumors, HC Wainwright price target $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8.X, Brookline buy rating βœ…οΈ $INAB previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone, achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (Ξ³Ξ΄) T cell-based therapies targeting cancer and autoimmune diseases
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 1:26 PM
πŸŒ… Watchlist βœ… $GLE .60 support, if above .75, have potential to .85/1.20 βœ… $ATRA low 7 support, if above 7.60, have potential to 8/8.50 βœ… $ERNA 6.50 support, if above 7, have potential to 7.50/.80 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 1:26 PM
πŸŒ… Watchlist part 2 βœ… $RMSG 1.50 support, if above 1.80, have potential to 2/2.40 βœ… $SABR low 2 support, if above 2.35, have potential to 2.50/.70 βœ… $NNBR 2.60 support, if above 3, have potential to 3.40/.50 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 2:17 AM
πŸŒ… Watchlist PART 2 βœ… $BYND slow and steady, trying to hold $1 ⚠️ $CHSN 1/100 reverse split, new price ~1.56 ⚠️ $CVNA 5/1 forward stock split, new price ~77.8 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 βœ… Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $INAB $ENLV still in swing accumulation phase 🎯🎯 Goal is GREEN πŸ€‘πŸ€‘ not GREED πŸ₯΅πŸ₯΅
0 Β· Reply
aletz
aletz May. 6 at 12:25 PM
$INAB https://investors.in8bio.com/news-releases/news-release-details/in8bio-showcase-next-generation-t-cell-engager-platform-and-new
1 Β· Reply
mangingriskandcandles
mangingriskandcandles May. 4 at 6:48 PM
$CHAI $HYFM $IMMR (As long as above 6.45) $INAB $IIPR earnings tomorrow
0 Β· Reply
SkywalkerAR
SkywalkerAR May. 2 at 3:10 PM
$INAB https://www.accessnewswire.com/newsroom/en/business-and-professional-services/redchips-biotech-virtual-investor-conference-replays-now-availab-1158944
0 Β· Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 4:30 PM
$INAB Current Stock Price: $1.55
0 Β· Reply
aletz
aletz Apr. 28 at 2:43 PM
$INAB https://in8bio.com/careers/ IN8bio is hiring! It’s a positive sign to see the company making progress in the field of TCE and expanding the team.
0 Β· Reply
aletz
aletz Apr. 22 at 2:37 PM
$INAB https://www.youtube.com/watch?v=xThHoXfV2lE Latest presentation by CEO William Ho: Here are a few notable updates on upcoming catalysts: 1) R&D Day is scheduled for May 21st. 2) TCE Mice data is expected between Q3 and Q4. 3) An AML update will be presented at ASH in December. 4) A peer-reviewed publication on GBM and FDA guidance is expected in near future. I look forward to seeing some meaningful updates on R&D Day next month.
0 Β· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 10:54 PM
$INAB RSI: 52.73, MACD: -0.0881 Vol: 0.15, MA20: 1.48, MA50: 1.66 πŸ”΄ SELL - Downtrend πŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 Β· Reply
aletz
aletz Apr. 8 at 5:59 PM
$INAB https://www.redchip.com/webinar/redchip/84347130169
0 Β· Reply
IN8bio
IN8bio Apr. 7 at 5:07 PM
Save the Date: May 21 2026 We’ll be hosting our R&D Day with updates on our: β€’ Glioblastoma (GBM) program β€’ Gamma-delta T cell engager platform Virtual option available πŸ‘‡ πŸ”— Register today by visiting https://investors.in8bio.com and navigating to the β€œEvents and Presentations” section. $INAB
0 Β· Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Apr. 7 at 4:22 PM
$INAB
0 Β· Reply
IN8bio
IN8bio Apr. 6 at 3:58 PM
Biotech = cycles Capital = follows what’s working Our CEO on GLP-1s + where innovation fits πŸ‘‡ Listen here: β€’https://open.spotify.com/episode/7pV0sl2dLbAKHMaoxw5LqI?si=EhVs_3pjS5mHKnh877Qm1Q&nd=1&dlsi=260b7b0600c348d6 β€’https://raisingbiotech.com/episode/s4-e4-the-weight-of-the-moment-how-glp-1s-are-rewiring-biotech-investing-expert-analysis β€’https://podcasts.apple.com/us/podcast/s4 $INAB
0 Β· Reply
IN8bio
IN8bio Apr. 2 at 3:20 PM
Solid tumors have been one of the toughest challenges in oncology. New science is starting to change that. Great to see our work featured by Genetic Engineering & Biotechnology News! πŸ”— https://www.genengnews.com/topics/cancer/engineering-biology-to-fight-cancer/ $INAB
0 Β· Reply